Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

By
Emily Salmini
-
0
80
In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associated with resistance to therapy.
[Cancer Discovery]
Abstract